ALEPH-6 Stats & Data

Only one lightly active human trial is published in PIHKAL: 30 mg oral produced a subtle (+1) effect that remained essentially unchanged at 12 hours, and Shulgin lists the dosage merely as 'greater than 40 mg' with 'probably long' duration, so any dosing beyond micro‑trials is speculative and risky. The slow onset (often ≥60 minutes) and very long tail create a strong temptation to redose too early; given that even 30 mg remained steady for 12 hours, redosing within the first half‑day could compound into an unexpectedly intense and prolonged experience. PIHKAL notes pronounced synergy when ALEPH‑6 was used as a 'primer' for LSD and followed later by cannabis, consistent with broader guidance that cannabis and classical psychedelics can produce unpredictable potentiation—plan set/setting accordingly and avoid polydrug use on first trials. Within the sulfur‑containing phenethylamine family, severe adverse outcomes have been documented for 2C‑T‑7 (including deaths, especially with insufflation and with MDMA co‑use); while ALEPH‑6 is a different compound, this history argues for extra caution with thio‑substituted phenethylamines. Combining classical psychedelics with lithium has been associated with seizures and extreme reactions; those prescribed lithium should avoid experimentation entirely. Because this compound is rare, mislabeling or adulteration is a major risk; use reagent testing (multi‑reagent) and, where possible, send a small sample to a lab‑based drug checking service before any bioassay. Given the lack of pharmacokinetic data, those with cardiovascular disease, seizure disorders, or a personal/family history of psychotic or bipolar spectrum illness should abstain; if anyone proceeds despite risks, they should use meticulous volumetric dosing, a milligram scale, a trusted sober sitter, and have a plan to manage an acute crisis (e.g., access to medical care; some communities use prescribed benzodiazepines under medical advice to terminate overwhelming trips).